Abstract | IMPORTANCE OF THE FIELD: AREAS COVERED IN THIS REVIEW: This review covers the activity of lenalidomide in multiple myeloma, efficacy in both newly diagnosed and relapsed/refractory patients, how to manage effectively common adverse events observed with lenalidomide, and its potential use in new settings based on clinical trials published up to 2009. WHAT THE READER WILL GAIN: This review describes the mechanism of action of lenalidomide in myeloma which provides the basis for its clinical use in newly diagnosed, relapsed/refractory, and high-risk smoldering myeloma in combination with other agents. Strategies to reduce or effectively manage myelosuppression and thromboembolic events, the main adverse events associated with lenalidomide plus dexamethasone therapy, are also described. TAKE HOME MESSAGE:
Lenalidomide is an oral immunomodulatory drug that is highly effective in treating multiple myeloma, has a favorable safety profile and is now being evaluated as maintenance therapy, preventive therapy and in combination with other new agents.
|
Authors | Jerome B Zeldis, Robert D Knight, Christian Jacques, Alison Tozer, Jean-Pierre Bizzari |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 5
Pg. 829-42
(Apr 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20210686
(Publication Type: Journal Article, Review)
|
Chemical References |
- Thalidomide
- Dexamethasone
- Lenalidomide
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, pharmacology, therapeutic use)
- Clinical Trials as Topic
- Dexamethasone
(administration & dosage)
- Humans
- Lenalidomide
- Multiple Myeloma
(drug therapy, mortality)
- Neoplasm Recurrence, Local
- Survival Rate
- Thalidomide
(administration & dosage, analogs & derivatives)
|